BUY MORE

07/15/14 07:47AM EDT

CLIENT TALKING POINTS

GOLD

Newsy call by Goldman yesterday reiterating what’s been the wrong call in 2014. Gold futures/options contract volume was +27% versus the 5-day average on that, but neither our TRADE line of $1301 support, nor implied volatility (still -2% on a 1 month basis) confirmed the 1-day fear. Buy more!  

UST 10YR

If you ask the bond market about yesterday’s Goldman Sachs’ call on Gold or consensus U.S. growth acceleration hopes in Q3, it doesn’t care – 10yr yield right back to 2.53% this morning with immediate-term downside to 2.49% into Yellen’s testimony.

EUROPE

Lines of immediate-term TRADE resistance that matter to us most are EuroStoxx50 = 3241, DAX 9855, and FTSE 6788. We are happy to let the market tell us which way to go in European equities for July and August.

TOP LONG IDEAS

HOLX

HOLX

Hologic is emerging from an extremely tough period which has left investors wary of further missteps. In our view, Hologic and its new management are set to show solid growth over the next several years. We have built two survey tools to track and forecast the two critical elements that will drive this acceleration.  The first survey tool measures 3-D Mammography placements every month.  Recently we have detected acceleration in month over month placements.  When Hologic finally receives a reimbursement code from Medicare, placements will accelerate further, perhaps even sooner.  With our survey, we'll see it real time. In addition to our mammography survey. We've been running a monthly survey of OB/GYNs asking them questions to help us forecast the rest of Hologic's businesses, some of which have been faced with significant headwinds. Based on our survey, we think those headwinds are fading. If the Affordable Care Act actually manages to reduce the number of uninsured, Hologic is one of the best positioned companies.

OC

OC

Construction activity remains cyclically depressed, but has likely begun the long process of recovery.  A large multi-year rebound in construction should provide a tailwind to OC shares that the market appears to be underestimating.  Both residential and nonresidential construction in the U.S. would need to roughly double to reach post-war demographic norms.  As credit returns to the market and government funded construction begins to rebound, construction markets should make steady gains in coming years, quarterly weather aside, supporting OC’s revenue and capacity utilization.

LM

LM

Legg Mason reported its month ending asset-under-management for April at the beginning of the week with a very positive result in its fixed income segment. The firm cited “significant” bond inflows for the month which we calculated to be over $2.3 billion. To contextualize this inflow amount we note that the entire U.S. mutual fund industry had total bond fund inflows of just $8.4 billion in April according to the Investment Company Institute, which provides an indication of the strong win rate for Legg alone last month. We also point out on a forward looking basis that the emerging trends in the mutual fund marketplace are starting to favor fixed income which should translate into accelerating positive trends at leading bond fund managers. Fixed income inflow is outpacing equities thus far in the second quarter of 2014 for the first time in 9 months which reflects the emerging defensive nature of global markets which is a good environment for leading fixed income houses including Legg Mason.

Asset Allocation

CASH 14% US EQUITIES 8%
INTL EQUITIES 10% COMMODITIES 22%
FIXED INCOME 24% INTL CURRENCIES 22%

THREE FOR THE ROAD

TWEET OF THE DAY

Reynolds American To Acquire Lorillard In Transaction Valued At $27.4 Billion, or $68.88.

@HedgeyeStaples

QUOTE OF THE DAY

The way of the pioneer is always rough.

-Harvey S. Firestone

STAT OF THE DAY

Despite yesterday’s sell-off in Gold the shiny commodity remains up +9% year-to-date and the UST 10yr Bond Yield is down -17% year-to-date.

© 2024 Hedgeye Risk Management, LLC. The information contained herein is the property of Hedgeye, which reserves all rights thereto. Redistribution of any part of this information is prohibited without the express written consent of Hedgeye. Hedgeye is not responsible for any errors in or omissions to this information, or for any consequences that may result from the use of this information.